Literature DB >> 7572251

Lithium prophylaxis of manic-depressive disorder: daily lithium dosing schedule versus every second day.

H V Jensen1, P Plenge, E T Mellerup, K Davidsen, L Toftegaard, H Aggernaes, N Bjørum.   

Abstract

The prophylactic efficacy of lithium carbonate given every second day versus daily intake was compared in a double-blind study including 50 manic-depressive patients. The patients met the DSM-III-R criteria for bipolar disorder or depressive disorder; according to ICD-8 the patients fulfilled criteria for manic-depressive disorder: All patients had experienced at least 3 episodes of mania or major depression, and all had been euthymic for at least 4 months. The median doses of lithium carbonate given were 800 mg/day or 1200 mg/every second day corresponding to median 12-h serum lithium concentrations of 0.6 mmol/l or 0.7 mmol/l, respectively. Manic or depressive relapse was defined as DSM-III-R criteria for mania or major depression, and a score > or = 10 on the Bech-Rafaelsen Mania Scale or the Bech-Rafaelsen Melancholia Scale, respectively. The two treatment schedules were allocated at random. Using the Cox proportional hazard model for statistical analysis, the lithium dosing schedule of every second day did not maintain its prophylactic efficacy against recurrent episodes of manic-depressive disorder. The risk of relapse increased 3 times when the interval between intake of lithium was extended from 1 to 2 days.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572251     DOI: 10.1111/j.1600-0447.1995.tb09545.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  9 in total

Review 1.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

Review 2.  Lithium and the kidney: an updated review.

Authors:  M Gitlin
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

3.  Urinary excretion of albumin and transferrin in lithium maintenance treatment: daily versus alternate-day lithium dosing schedule.

Authors:  H V Jensen; J Holm; K Davidsen; L Toftegaard; H Aggernaes; N Bjørum
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

4.  Twelve-hour brain lithium concentration in lithium maintenance treatment of manic-depressive disorder: daily versus alternate-day dosing schedule.

Authors:  H V Jensen; P Plenge; A Stensgaard; E T Mellerup; C Thomsen; H Aggernaes; O Henriksen
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

Review 5.  Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations.

Authors:  Gin S Malhi; Michelle Tanious
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

Review 6.  The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: a 20-year review of its use as an outcome measure.

Authors:  Per Bech
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 7.  Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 8.  An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms.

Authors:  Eunsoo Won; Yong-Ku Kim
Journal:  Int J Mol Sci       Date:  2017-12-11       Impact factor: 5.923

9.  Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: an overview.

Authors:  R J Baldessarini; L Tondo
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 3.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.